Search results
Results From The WOW.Com Content Network
Esperion Therapeutics. Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a ...
How do we determine whether Esperion Therapeutics, Inc. (NASDAQ:ESPR) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world ...
Bempedoic acid. Bempedoic acid, sold under the brand name Nexletol among others, is a medication for the treatment of hypercholesterolemia (high blood cholesterol levels). [2] [3] The most common side effects include hyperuricemia (high blood levels of uric acid), pain in arms or legs, and anemia (low red blood cell counts). [3]
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion Therapeutics, a high tech venture capital start-up, demonstrated efficacy in both animals and humans, spending many millions of dollars over several years to conduct a single human trial which showed impressive and rapid efficacy by IVUS of coronary arteries. However, over the course of the project they produced only enough ApoA-I ...
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 8.24% and -1.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Esperion, the company that makes and markets bempedoic acid, sells it alone or coupled with a second cholesterol-lowering medication, called ezetimibe. Both versions are priced at $395 per month ...